Welcome to our dedicated page for Aspira Women`s Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health stock.
Aspira Women’s Health Inc. (formerly trading on Nasdaq under AWH) generates frequent news as a bio-analytical based women’s health company focused on noninvasive, AI-powered diagnostic tests for gynecologic diseases. Its updates often center on the commercial performance of OvaSuiteSM, which includes the OvaWatch® and Ova1Plus® blood tests for assessing ovarian cancer risk in women with adnexal masses.
News coverage commonly includes quarterly and annual financial results, where Aspira reports product revenue, OvaSuite test volumes, gross profit, operating expenses, and net loss. These releases may also describe changes in sales productivity, cost controls, and balance sheet items such as cash, liabilities, and stockholders’ deficit.
Another key category of Aspira news involves its research and development pipeline, particularly the ENDOinform™ program. The company has issued multiple announcements about its milestone-based award from the ARPA-H Sprint for Women’s Health initiative, detailing milestone achievements, associated cash payments, and progress toward a non-invasive, AI-enabled blood test for endometriosis using protein and microRNA biomarkers plus patient data.
Corporate governance and capital markets developments are also frequent topics. Aspira has reported Board and executive appointments, equity and convertible note financings, and changes in its listing status, including a delisting notification from Nasdaq and subsequent trading on OTC markets under related symbols. Together, these news items provide investors and observers with insight into Aspira’s diagnostic portfolio, pipeline evolution, financial condition, and corporate actions.
For anyone tracking AWH-related news, this page aggregates press releases and other coverage related to ovarian cancer risk assessment tests, endometriosis diagnostics development, ARPA-H milestones, financial updates, and boardroom or listing changes.
Summary not available.
Summary not available.
Summary not available.
Aspira Women’s Health reported a 20% year-over-year revenue increase to $8.2 million for 2022, with OvaSuiteSM volume rising 23% to 21,423 units. The fourth quarter revenue was $2.2 million, up 16% from the previous year, driven by an 18% increase in tests performed. However, revenue per test decreased by 3% due to a shift towards Medicaid. The company achieved a gross profit margin of 57% in Q4 and 53% for the year. Aspira successfully launched the OvaWatch test and aims to introduce EndoCheck™ this year. Cash utilization decreased to $7.1 million in Q4 compared to $10.2 million earlier in the year, with projected 2023 cash utilization between $16 million and $19 million.
Aspira Women’s Health (Nasdaq: AWH) has announced it will release its financial results for the year ended December 31, 2022, on March 22, 2023, after market close. Management will host a conference call at 4:30 PM ET to discuss these results and provide updates on corporate developments. The call can be accessed via toll-free and international numbers, with a dedicated conference ID of 13736207. Aspira is focused on innovative testing options for gynecological health, including Ova1Plus®, aimed at detecting ovarian malignancy risks, and EndoCheck™, a test for endometriosis currently in development.
Aspira Women’s Health Inc. (AWH) announced that a leading national health insurance provider has agreed to cover its OvaWatch ovarian cancer test, launched in December 2022. This coverage will minimize out-of-pocket expenses for patients and is based on recent evidence supporting OvaWatch's clinical validation. Nicole Sandford, President and CEO, expressed satisfaction with the recognition of OvaWatch's value in ovarian cancer risk management. OvaWatch features a 99% negative predictive value, assisting physicians in effectively assessing ovarian cancer risk and determining appropriate treatments.
Aspira Women’s Health reported significant growth in preliminary fourth quarter metrics for 2022, with OvaSuite tests increasing 23% year-over-year to 21,424. The number of tests for Q4 rose 18% compared to the previous year, reaching 5,643. Average daily test volume peaked at 86.6. The company met cash utilization guidance for the quarter, estimating between $6 million and $8 million. Aspira aims to save $6 million in 2023 by reducing staff without impacting growth plans.
Aspira Women’s Health has released promising clinical data supporting its OvaWatch assay for assessing ovarian cancer risk in women with adnexal masses. Published in Frontiers in Medicine, the study highlights OvaWatch's high negative predictive value (NPV) of 99%, underscoring its effectiveness in identifying potential malignancies. In a multi-site clinical analysis, OvaWatch identified 18 out of 22 malignancies missed by physicians. The assay aims to reduce unnecessary surgeries and enhance patient care, marking a significant advancement in non-invasive ovarian cancer diagnostics.
Aspira Women’s Health announced expanded Medicare coverage for multi-marker tests for ovarian cancer through the 2023 Omnibus Spending Bill, following a new PLA Code approval for OvaWatch by the AMA. The bill aims to enhance access for women facing pelvic masses and encourages commercial payers to follow suit. Additionally, Medicaid coverage for Ova1Plus has expanded to five states, now totaling 27. This progress underscores Aspira's commitment to improving ovarian cancer diagnostics alongside ongoing legislative advocacy.
Aspira Women’s Health has launched OvaWatch, a non-invasive blood test to assess ovarian cancer risk in women with adnexal masses. Available from December 1, 2022, OvaWatch features a 99% negative predictive value, helping physicians rule out malignancy. This expansion of the OvaSuite portfolio aims to benefit a larger patient population and improve early ovarian cancer detection. The company anticipates strong demand and broad payer coverage for OvaWatch, reinforcing its commitment to women's health diagnostics.